Behavioral Disciplines and Activities

28 trials 7 recruiting

Filter these 28 trials by phase, country and sponsor.

Open in Search →

Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin a… Not authorised

2023-505253-41-00 Autism Spectrum Disorder (ASD) 5
Trial of Cannabidiol for the treatment of alcohol dependence Not authorised

2023-504439-42-00 alcohol dependence 4
Trial of Cannabidiol for the treatment of alcohol dependence Not authorised

2023-504439-42-01 alcohol dependence 4
EPABID: Efficacy of Pipamperone and Aripiprazole on Behaviors that challenge in Intellectual Disabilities Pending

2024-519833-51-00 Behaviors that challenge 6
OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety Pending

2024-513894-35-00 Depression 4
THE EFFECT OF ROPINIROLE ON FUNCTIONAL CONNECTIVITY AND METACOGNITION IN HEALTHY SUBJECTS Pending

2025-520800-81-00 Healthy volunteers (mechanistic study evaluating the ef 10
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1) Recruiting

2025-522313-38-00 Alcohol Use Disorder 5 2026-03-06
BACLOFEN FOR IMPROVING BENZODIAZEPINE TITRATION IN BENZODIAZEPINE DEPENDENCE. BABET Recruiting

2022-502307-30-00 Psychiatrics disorders, addictology 10 2026-01-15
Methylphenidate in KBG syndrome Recruiting

2023-506202-40-01 KBG syndrome 6 2024-10-01
EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized… Recruiting

2024-516902-46-00 Attention Deficit Hyperactivity Disorder (ADHD) 10 2024-09-19
Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin a… Recruiting

2023-505253-41-01 Autism Spectrum Disorder (ASD) 5 2024-06-18
Evaluation of the effectiveness of the reconsolidation therapy in a clinical population suffering from post-traumatic stress disorder Recruiting

2022-500870-32-02 Post-traumatic stress disorder 4 2023-10-04
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Recruiting

2023-505625-14-00 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r 7 2017-01-31
A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact… Ended

2022-502606-33-00 Patients with histologically or cytologically documente 5 2021-02-26
A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl… Ended

2023-506524-82-00 Stage IB-IIIA non-small cell lung carcinoma, with a cen 5 2015-10-21
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrex… Ended

2024-519776-20-00 Alcohol dependence 2 2025-05-12
An open-label, randomised, single-dose, three-way cross-over trial to assess the pharmacokinetics of NIC24-01 and NIC24-02 oromucosal pouche… Ended

2024-514676-40-00 Nicotine dependence 3 2024-12-12
A study to investigate the mass balance, absolute bioavailability (BA), pharmacokinetics (PK), and metabolism of a single oral dose 60 mg [1… Ended

2023-506044-16-00 There is no medical condition being investigated. 3 2023-12-14
A phase I randomized, investigator and participant-blind, adaptive, multiple-ascending dose, parallel and four-way crossover, placebo-contro… Ended

2023-504794-20-00 Healthy participants (part 1 and part 2) 3 2023-10-26
Safety and efficacy of olanzapine treatment in psychosis: Effect of genetic and epigenetic factors – covariates of treatment response Ended

2022-502902-33-00 Psychoses 6 2023-10-24
A superiority study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome Ended

2024-511673-30-00 Pediatric acute-onset neuropsychiatric syndrome (PANS) 5 2023-03-20
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytis… Ended

2022-500921-34-00 Nicotine addiction 3 2022-12-13
A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisin… Ended

2022-500954-40-00 Nicotine addiction 3 2022-10-17
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30